Jane Street Group LLC Sells 5,507 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Jane Street Group LLC decreased its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 19.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,176 shares of the biotechnology company’s stock after selling 5,507 shares during the period. Jane Street Group LLC’s holdings in Enanta Pharmaceuticals were worth $240,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $122,000. American Century Companies Inc. boosted its position in shares of Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 7,287 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after purchasing an additional 18,003 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $1,243,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $903,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $5.09 on Friday. The stock’s 50 day simple moving average is $7.86 and its 200 day simple moving average is $11.00. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.87 and a fifty-two week high of $17.80. The company has a market cap of $107.86 million, a P/E ratio of -0.93 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The company had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same period last year, the company earned ($1.33) earnings per share. Equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.73 earnings per share for the current year.

Analyst Ratings Changes

ENTA has been the topic of several research analyst reports. HC Wainwright cut their target price on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, December 24th. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Finally, Robert W. Baird dropped their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 13.64% of the company’s stock.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.